The treatment rates for Cushing's syndrome are rising, bringing more attention to Corcept Therapeutics — the stock is likely to break out of the base at its all-time high soon!

Corcept Therapeutics focuses on the development of medications that regulate cortisol levels. With Korlym, the company has a drug on the market that has driven strong revenue growth for years and is used for the treatment of Cushing's syndrome. Cortisol is also known as the stress hormone, but excessive amounts can lead to a variety of disorders and diseases. Since 2016, the company has been profitable, with revenue expected to increase by 40 to 45% to $700 million by the end of fiscal year 2024. For the year 2025, consensus estimates only forecast...